Blog | HemaCare

A New Immunotherapy May Allow a Reawakening of the Immune System

Jan 11, 2022 10:30:00 AM / by Stacy Matthews Branch, DVM, PhD posted in T Cells, Tumors, Immunotherapy (Immunology)


Researchers found that one’s immune system can re-engage to destroy tumors after combining chemotherapy and immunotherapy in mice.

Chemotherapy remains the first-line approach for the treatment of solid tumors. It is based on the cytotoxic activity on rapidly dividing cells, but adverse effects are seen on healthy cells that also rapidly divide, such as the intestinal mucosal lining, and hair follicles. 

Read More

HemaCare PBMCs Used for Study That Puts SARS-Cov-2 Under the Magnifying Glass

Nov 16, 2021 10:15:00 AM / by Nancy Andon, MSc posted in Cytotoxic T Cells, Dendritic Cells, PBMCs, T Cells


An independent study published by the MD Anderson Cancer Center in Houston TX cites using HemaCare PBMCs to take a closer look at the SARS-CoV-2 virus to identify which of its peptide sequences would make the most effective vaccine targets.

Early in the COVID-19 pandemic, the primary goal for scientists across the globe was to save lives by developing a safe, working vaccine as quickly as possible. To that end, they succeeded admirably; with several vaccines approved, doctors finally have a powerful way to fight back against this deadly disease.

Read More

HemaCare Apheresis Materials Aid COVID-19 Vaccine Clinical Trial

Oct 12, 2021 10:30:00 AM / by Nancy Andon, MSc posted in Apheresis, T Cells


Researchers involved in the clinical investigation of a new COVID-19 vaccine cited using HemaCare healthy donor starting materials for their study.

The scientists, most of whom work at ImmunityBio in Culver City, CA, are conducting a Phase 1 clinical trial for their new dual-antigen COVID-19 vaccine. [1]

Read More

HemaCare T Cells Support Study on Cell Therapy Consistency

Oct 5, 2021 10:30:00 AM / by Nancy Andon, MSc posted in Leukopak, Cancer, T Cells


A new publication by scientists at the Cell and Gene Therapy Catapult in the UK cites the use of HemaCare-sourced CD3+ T cells for their cancer immunotherapy research.

The successful commercialization of gene-modified cell therapies relies in part on being able to manufacture a consistent product. Many cell and gene therapy developers use lentiviral vector delivery systems to impart the therapeutic gene modifications necessary to making their therapies effective.

Read More

HemaCare PBMCs used for 3D Anti-Tumor Discovery Platform

Sep 28, 2021 10:30:00 AM / by Nancy Andon, MSc posted in Cryopreservation, PBMCs, T Cells, Immunotherapy (Immunology)


An independent publication cites the use of HemaCare-sourced PBMC as starting material for an assay designed to screen for factors that enhance anti-tumor cytotoxic T cell activity. [1]

The paper, published in the renowned scientific journal Nature, reports the study results of a scientific team working at Novartis in San Diego. Their goal is to develop a discovery platform that more closely mimics the in-vivo tumor microenvironment.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts